Kanika Dey
Overview
Explore the profile of Kanika Dey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
3
Citations
354
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Levin M, Ustianowski A, De Wit S, Beavon R, Thissen J, Seegobin S, et al.
Infect Dis Ther
. 2024 May;
13(6):1253-1268.
PMID: 38703336
Introduction: The phase 3 PROVENT and STORM CHASER studies evaluated AZD7442 (tixagevimab/cilgavimab) for pre-exposure and post-exposure prophylaxis of symptomatic coronavirus disease 2019 (COVID-19). We report the final 15-month results of...
2.
Levin M, Ustianowski A, Thomas S, Templeton A, Yuan Y, Seegobin S, et al.
Clin Infect Dis
. 2022 Nov;
76(7):1247-1256.
PMID: 36411267
Background: This phase 3 trial assessed AZD7442 (tixagevimab/cilgavimab) for post-exposure prophylaxis against symptomatic coronavirus disease 2019 (COVID-19). Methods: Adults without prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or...
3.
Levin M, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, et al.
N Engl J Med
. 2022 Apr;
386(23):2188-2200.
PMID: 35443106
Background: The monoclonal-antibody combination AZD7442 is composed of tixagevimab and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that have an extended half-life and have been...